Reneuron Group (OTC) (GB:RENE) has released an update.
ReNeuron Group plc, a UK-based leader in stem cell derived exosome technologies, has provided an update on its administration process initiated on 20 March 2024. The company is exploring several options to secure its future, including a potential equity fundraise or sale of its assets, alongside cost rationalization efforts which have led to staff redundancies. Key senior management remains to support the administrators during this challenging period.
For further insights into GB:RENE stock, check out TipRanks’ Stock Analysis page.
